Display options
Cite
Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016;12:917-29doi: 10.2147/NDT.S88632.
Montemagni, C., Frieri, T., & Rocca, P. (2016). Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatric disease and treatment, 12917-29. https://doi.org/10.2147/NDT.S88632
Montemagni, Cristiana, et al. "Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life." Neuropsychiatric disease and treatment vol. 12 (2016): 917-29. doi: https://doi.org/10.2147/NDT.S88632
Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016 Apr 19;12:917-29. doi: 10.2147/NDT.S88632. eCollection 2016. PMID: 27143893; PMCID: PMC4844443.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2016 Apr 19;12:917-29. doi: 10.2147/NDT.S88632. eCollection 2016.

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Neuropsychiatric disease and treatment

Cristiana Montemagni, Tiziana Frieri, Paola Rocca

Affiliations

  1. Department of Neuroscience, Unit of Psychiatry, University of Turin, Italy; Department of Mental Health, Azienda Sanitaria Locale (ASL) Torino 1 (TO1), Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy.

PMID: 27143893 PMCID: PMC4844443 DOI: 10.2147/NDT.S88632

Abstract

Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting formulation. The purpose of this review is to evaluate the available literature concerning the impact of SGA-LAIs on patient functioning and quality of life (QOL). Although several studies regarding schizophrenia patients' functioning and QOL have been performed, the quantity of available data still varies greatly depending on the SGA-LAI under investigation. After reviewing the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or QOL of patients with schizophrenia, as compared with placebo. However, while methodological design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, the significant amount of evidence in recently published research demonstrates the beneficial influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking in several aspects that may help physicians in choosing the correct drug therapy. Meaningful differences have been observed between SGA-LAIs in the onset of their clinical efficacy and in the relationships between symptoms and functioning scores. Moreover, head-to-head studies comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning are available mainly on risperidone LAI, while those comparing olanzapine LAI with other SGA-LAIs are still lacking. Lastly, some data on their use, especially in first-episode or recent-onset schizophrenia and in refractory or treatment-resistant schizophrenia, is available.

Keywords: first-episode schizophrenia; outcome; recent-onset schizophrenia; treatment resistant schizophrenia

References

  1. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8 - PubMed
  2. Hum Psychopharmacol. 2007 Dec;22(8):505-13 - PubMed
  3. J Psychopharmacol. 2015 Aug;29(8):910-22 - PubMed
  4. Neuropsychopharmacology. 1996 Mar;14(3 Suppl):13S-21S - PubMed
  5. Int Clin Psychopharmacol. 2005 May;20(3):121-30 - PubMed
  6. Aust N Z J Psychiatry. 2010 Oct;44(10):921-8 - PubMed
  7. Schizophr Res. 2011 Oct;132(1):28-34 - PubMed
  8. JAMA Psychiatry. 2013 Sep;70(9):913-20 - PubMed
  9. Acta Psychiatr Scand. 2014 Dec;130(6):427-38 - PubMed
  10. Ther Adv Psychopharmacol. 2015 Oct;5(5):278-88 - PubMed
  11. Neuropsychopharmacology. 2010 Sep;35(10):2072-82 - PubMed
  12. BMC Psychiatry. 2010 Jan 07;10:2 - PubMed
  13. Int Clin Psychopharmacol. 2013 Mar;28(2):57-66 - PubMed
  14. N Engl J Med. 2011 Mar 3;364(9):842-51 - PubMed
  15. BMJ. 2014 Feb 12;348:g1173 - PubMed
  16. J Clin Psychiatry. 2007 Nov;68(11):1751-62 - PubMed
  17. Int Clin Psychopharmacol. 2014 Nov;29(6):322-31 - PubMed
  18. Int Clin Psychopharmacol. 2007 Mar;22(2):85-92 - PubMed
  19. Int Clin Psychopharmacol. 2010 Sep;25(5):247-56 - PubMed
  20. Schizophr Bull. 2010 Jan;36(1):71-93 - PubMed
  21. J Clin Psychiatry. 2009 Jul;70(7):990-6 - PubMed
  22. Schizophr Res. 2014 May;155(1-3):52-8 - PubMed
  23. Br J Psychiatry. 2007 Aug;191:131-9 - PubMed
  24. Ann Gen Psychiatry. 2011 Apr 11;10(1):12 - PubMed
  25. Schizophr Res. 2011 Apr;127(1-3):83-92 - PubMed
  26. Neuropsychiatr Dis Treat. 2014 Jun 20;10:1125-31 - PubMed
  27. Innov Clin Neurosci. 2011 Aug;8(8):26-33 - PubMed
  28. J Psychopharmacol. 2005 Sep;19(5 Suppl):32-8 - PubMed
  29. BMJ Case Rep. 2015 Aug 26;2015:null - PubMed
  30. J Psychopharmacol. 2008 May;22(3):254-61 - PubMed
  31. J Clin Psychiatry. 2005 Jul;66(7):831-8 - PubMed
  32. J Med Assoc Thai. 2010 Mar;93(3):343-50 - PubMed
  33. J Clin Psychopharmacol. 2010 Apr;30(2):200-2 - PubMed
  34. World Psychiatry. 2013 Oct;12(3):216-26 - PubMed
  35. Int Clin Psychopharmacol. 2008 Nov;23(6):325-31 - PubMed
  36. Schizophr Bull. 2008 Nov;34(6):1163-71 - PubMed
  37. Eur Psychiatry. 2009 Jun;24(5):287-96 - PubMed
  38. Acta Psychiatr Scand. 2002 Oct;106(4):286-90 - PubMed
  39. Hum Psychopharmacol. 2014 Sep;29(5):414-26 - PubMed
  40. Schizophr Res. 2010 Sep;122(1-3):1-23 - PubMed
  41. Br J Psychiatry. 2005 Aug;187:131-6 - PubMed
  42. J Clin Psychopharmacol. 2010 Apr;30(2):169-75 - PubMed
  43. Psychiatr Serv. 2007 Sep;58(9):1187-92 - PubMed
  44. Schizophr Res. 2015 Oct;168(1-2):498-504 - PubMed
  45. BMC Psychiatry. 2011 Oct 14;11:167 - PubMed
  46. Psychiatr Serv. 2003 May;54(5):665-7 - PubMed
  47. Clin Psychopharmacol Neurosci. 2011 Aug;9(2):45-53 - PubMed
  48. BMC Psychiatry. 2013 Dec 20;13:340 - PubMed
  49. Schizophr Res. 2009 Mar;108(1-3):214-22 - PubMed
  50. Hum Psychopharmacol. 2009 Oct;24(7):574-83 - PubMed
  51. Schizophr Bull. 2014 Jan;40(1):192-213 - PubMed
  52. Int Clin Psychopharmacol. 2014 Sep;29(5):279-87 - PubMed
  53. Ann Clin Psychiatry. 2007 Apr-Jun;19(2):65-71 - PubMed
  54. Schizophr Res Treatment. 2012;2012:764769 - PubMed
  55. Srp Arh Celok Lek. 2011 Dec;139 Suppl 1:36-40 - PubMed
  56. Encephale. 2007 Dec;33(6):973-81 - PubMed
  57. Psychiatry Res. 2010 Apr 30;176(2-3):109-13 - PubMed
  58. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:1-7 - PubMed
  59. Br J Psychiatry. 2004 Apr;184:346-51 - PubMed
  60. Schizophr Res. 2014 Apr;154(1-3):14-22 - PubMed
  61. Int J Neuropsychopharmacol. 2012 Feb;15(1):107-18 - PubMed
  62. J Nerv Ment Dis. 2014 Jan;202(1):13-7 - PubMed
  63. N Engl J Med. 2005 Sep 22;353(12 ):1209-23 - PubMed
  64. Eur Psychiatry. 2010 May;25(4):220-9 - PubMed
  65. J Clin Psychopharmacol. 2011 Feb;31(1):75-81 - PubMed
  66. Can J Psychiatry. 2005 Nov;50(13 Suppl 1):7S-57S - PubMed
  67. Can J Psychiatry. 2013 May;58(5 Suppl 1):30S-5S - PubMed
  68. Psychiatr Serv. 2004 Sep;55(9):997-1005 - PubMed
  69. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):218-26 - PubMed
  70. Schizophr Bull. 1995;21(4):645-56 - PubMed
  71. Expert Opin Pharmacother. 2012 Aug;13(11):1631-43 - PubMed
  72. J Psychiatr Pract. 2008 Sep;14(5):289-300 - PubMed
  73. Eur Psychiatry. 2012 Aug;27(6):401-5 - PubMed
  74. BMC Psychiatry. 2013 Feb 08;13:50 - PubMed
  75. Early Interv Psychiatry. 2014 Feb;8(1):39-49 - PubMed
  76. Pharmacopsychiatry. 2006 Jul;39(4):135-41 - PubMed
  77. Curr Med Res Opin. 2012 Mar;28(3):315-23 - PubMed
  78. Schizophr Res. 2015 Dec;169(1-3):506 - PubMed
  79. Am J Psychiatry. 2011 Jun;168(6):603-9 - PubMed
  80. World J Biol Psychiatry. 2013 Feb;14(1):2-44 - PubMed
  81. J Clin Psychiatry. 2013 Oct;74(10):957-65 - PubMed
  82. Br J Psychiatry Suppl. 1998;172(33):53-9 - PubMed
  83. Encephale. 2008 Apr;34(2):170-8 - PubMed
  84. Neuropsychiatr Dis Treat. 2013;9:1655-9 - PubMed
  85. J Clin Psychiatry. 2011;72 Suppl 1:9-13 - PubMed
  86. Pharmacopsychiatry. 2010 Mar;43(2):73-80 - PubMed
  87. J Clin Psychiatry. 2014 Nov;75(11):1254-60 - PubMed
  88. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1231-5 - PubMed
  89. Schizophr Res. 2012 Feb;134(2-3):219-25 - PubMed
  90. J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14 - PubMed
  91. Value Health. 2009 Jun;12 (4):536-43 - PubMed
  92. Lancet. 2008 Mar 29;371(9618):1085-97 - PubMed
  93. Psychiatr Rehabil J. 2004 Spring;27(4):345-59 - PubMed
  94. Health Qual Life Outcomes. 2012 Apr 02;10:35 - PubMed
  95. BMC Psychiatry. 2012 Aug 31;12 :130 - PubMed
  96. J Clin Psychiatry. 2004 Apr;65(4):531-6 - PubMed
  97. Int J Psychiatry Clin Pract. 2011 Nov;15(4):286-95 - PubMed
  98. Schizophr Res. 2014 Nov;159(2-3):415-20 - PubMed
  99. Hum Psychopharmacol. 2010 Apr;25(3):243-52 - PubMed
  100. Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13 - PubMed
  101. Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):487-95 - PubMed
  102. Int J Neuropsychopharmacol. 2005 Sep;8(3):427-38 - PubMed
  103. J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8 - PubMed
  104. Schizophr Bull. 1995;21(3):419-29 - PubMed
  105. Pharmacopsychiatry. 2007 Nov;40(6):257-63 - PubMed
  106. Med Care. 2004 Mar;42(3):200-9 - PubMed
  107. J Psychopharmacol. 2011 May;25(5):685-97 - PubMed
  108. Schizophr Res. 2012 Sep;140(1-3):1-8 - PubMed
  109. BMC Psychiatry. 2012 Mar 26;12:25 - PubMed
  110. Schizophr Bull. 1997;23(1):3-9 - PubMed
  111. Expert Opin Drug Deliv. 2016;13(2):253-64 - PubMed
  112. Acta Psychiatr Scand Suppl. 2003;(416):7-15 - PubMed
  113. J Clin Psychiatry. 2004 Aug;65(8):1084-9 - PubMed
  114. Curr Opin Psychiatry. 2015 May;28(3):216-21 - PubMed

Publication Types